ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
J

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant AML and HR-MDS

By ASH 2022 Conference Coverage FEATURING Jan Bewersdorf
By ASH 2022 Conference Coverage FEATURING Jan Bewersdorf
92 views
December 16, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
MDS and MPN
18:24

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

ASH 2022 Conference Coverage

T. Barbui

183 views
05:09

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

ASH 2022 Conference Coverage

U. Platzbecker

191 views
31:13

Selected Updates in MDS

ASH 2022 Conference Coverage

A. Zeidan

486 views
08:24

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

ASH 2022 Conference Coverage

A. Vannucchi

436 views
09:27

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

1.2K views
03:41

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

ASH 2022 Conference Coverage

G. Borthakur

177 views
06:04

ASH 2022 Real-World Validation of Molecular International Prognostic…

ASH 2022 Conference Coverage

M. Della Porta

49 views
11:00

ASH 2022: Management of Accelerated and Blast-Phase MPN

ASH 2022 Conference Coverage

R. Rampal

57 views
10:14

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

ASH 2022 Conference Coverage

F. Passamonti

77 views
27:09

ASH 2022: What Is Complete HLA Match in 2022?

ASH 2022 Conference Coverage

S. Spellman

193 views
06:34

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

ASH 2022 Conference Coverage

A. Patel

107 views
09:54

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

ASH 2022 Conference Coverage

A. Hoover

28 views
06:06

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

ASH 2022 Conference Coverage

R. Komrokji

282 views
06:55

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

ASH 2022 Conference Coverage

R. Komrokji

334 views
07:02

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

ASH 2022 Conference Coverage

D. Sallman

40 views
10:30

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

ASH 2022 Conference Coverage

A. Zeidan

132 views
06:10

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

ASH 2022 Conference Coverage

J. Mascarenhas

134 views
08:11

Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on…

ASH 2022 Conference Coverage

S. Ball

192 views
08:02

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

ASH 2022 Conference Coverage

S. Holtan

352 views
11:40

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Ther…

ASH 2022 Conference Coverage

A. Yacoub

57 views
08:57

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

ASH 2022 Conference Coverage

J. Bewersdorf

92 views
11:20

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…

ASH 2022 Conference Coverage

A. Gerds

233 views